These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36648003)

  • 1. Does the COVID-19 XBB Omicron subvariant signal the beginning of the end of the pandemic?
    Ngiam JN; Al-Mubaarak A; Maurer-Stroh S; Tambyah PA
    Singapore Med J; 2022 Dec; ():. PubMed ID: 36648003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A recombinant spike-XBB.1.5 protein vaccine induces broad-spectrum immune responses against XBB.1.5-included Omicron variants of SARS-CoV-2.
    He C; Alu A; Lei H; Yang J; Hong W; Song X; Li J; Yang L; Wang W; Shen G; Lu G; Wei X
    MedComm (2020); 2023 Jun; 4(3):e263. PubMed ID: 37125241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
    Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L
    J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial: The XBB.1.5 ('Kraken') Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread.
    Parums DV
    Med Sci Monit; 2023 Feb; 29():e939580. PubMed ID: 36722047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Rise of SARS-CoV-2 (COVID-19) Omicron Subvariant Pathogenicity.
    DeGrasse DC; Black SD
    Cureus; 2023 Jun; 15(6):e40148. PubMed ID: 37313287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rapid rise of SARS-CoV-2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants.
    Ao D; He X; Hong W; Wei X
    MedComm (2020); 2023 Apr; 4(2):e239. PubMed ID: 36938325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants.
    Patel N; Trost JF; Guebre-Xabier M; Zhou H; Norton J; Jiang D; Cai Z; Zhu M; Marchese AM; Greene AM; Mallory RM; Kalkeri R; Dubovsky F; Smith G
    Sci Rep; 2023 Nov; 13(1):19176. PubMed ID: 37932354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A New-fangled COVID-19 Variant, Eris, Might be the One to Lookout in 2023 or far from Over.
    Ray SK; Mukherjee S
    Infect Disord Drug Targets; 2024; 24(6):e220124225916. PubMed ID: 38258765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EG.5 (Eris) and BA.2.86 (Pirola) two new subvariants of SARS-CoV-2: a new face of old COVID-19.
    Esmaeilzadeh A; Ebrahimi F; Jahani Maleki A; Siahmansouri A
    Infection; 2024 Apr; 52(2):337-343. PubMed ID: 38170417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Analysis of Omicron Subvariants: EG.5 Rise, Vaccination Strategies, and Global Impact.
    Sil D; Gautam S; Saxena S; Joshi S; Kumar D; Mehta A; Jindal P; Sharma S; Pandey P; Diksha ; Singh A
    Curr Drug Targets; 2024; 25(8):517-525. PubMed ID: 38726782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86.
    Lasrado N; Collier AY; Hachmann NP; Miller J; Rowe M; Schonberg ED; Rodrigues SL; LaPiana A; Patio RC; Anand T; Fisher J; Mazurek CR; Guan R; Wagh K; Theiler J; Korber BT; Barouch DH
    Vaccine; 2023 Nov; 41(47):6904-6909. PubMed ID: 37872011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. XBB.1.16 Omicron subvariant rise to a variant of interest: Implications for global alertness and preparedness.
    John OO; Olabode ON; Lucero-Prisno Iii DE; Adebimpe OT; Singh A
    J Taibah Univ Med Sci; 2023 Dec; 18(6):1285-1287. PubMed ID: 37250814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo.
    Uraki R; Kiso M; Iwatsuki-Horimoto K; Yamayoshi S; Ito M; Chiba S; Sakai-Tagawa Y; Imai M; Kashima Y; Koga M; Fuwa N; Okumura N; Hojo M; Iwamoto N; Kato H; Nakajima H; Ohmagari N; Yotsuyanagi H; Suzuki Y; Kawaoka Y
    Cell Rep; 2023 Dec; 42(12):113580. PubMed ID: 38103202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics and novel mutations of omicron subvariant XBB in Tamil Nadu, India - a cohort study.
    Selvavinayagam ST; Karishma SJ; Hemashree K; Yong YK; Suvaithenamudhan S; Rajeshkumar M; Aswathy B; Kalaivani V; Priyanka J; Kumaresan A; Kannan M; Gopalan N; Chandramathi S; Vignesh R; Murugesan A; Anshad AR; Ganesh B; Joseph N; Babu H; Govindaraj S; Larsson M; Kandasamy SL; Palani S; Singh K; Byrareddy SN; Velu V; Shankar EM; Raju S
    Lancet Reg Health Southeast Asia; 2023 Dec; 19():100272. PubMed ID: 38076717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant.
    Khan K; Lustig G; Römer C; Reedoy K; Jule Z; Karim F; Ganga Y; Bernstein M; Baig Z; Jackson L; Mahlangu B; Mnguni A; Nzimande A; Stock N; Kekana D; Ntozini B; van Deventer C; Marshall T; Manickchund N; Gosnell BI; Lessells RJ; Karim QA; Abdool Karim SS; Moosa MS; de Oliveira T; von Gottberg A; Wolter N; Neher RA; Sigal A
    Nat Commun; 2023 Dec; 14(1):8078. PubMed ID: 38057313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. XBB.1.16-RBD-based trimeric protein vaccine can effectively inhibit XBB.1.16-included XBB subvariant infection.
    Peng D; He C; Chen Z; Lei H; Huang X; Ye C; Wang B; Hao Y; Du X; Lu S; Hu H; Cheng W; Dong H; Lei J; Zhou X; Song X; Lu G; Wei X
    MedComm (2020); 2024 Sep; 5(9):e687. PubMed ID: 39156763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural and functional characteristics of SARS-CoV-2 Omicron subvariant BA.2 spike.
    Zhang J; Tang W; Gao H; Lavine CL; Shi W; Peng H; Zhu H; Anand K; Kosikova M; Kwon HJ; Tong P; Gautam A; Rits-Volloch S; Wang S; Mayer ML; Wesemann DR; Seaman MS; Lu J; Xiao T; Xie H; Chen B
    bioRxiv; 2022 Apr; ():. PubMed ID: 35547850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural evolution of SARS-CoV-2 omicron in human receptor recognition.
    Zhang W; Shi K; Geng Q; Herbst M; Wang M; Huang L; Bu F; Liu B; Aihara H; Li F
    J Virol; 2023 Aug; 97(8):e0082223. PubMed ID: 37578233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applications of peptide-functionalized or unfunctionalized selenium nanoparticles for the passivation of SARS-CoV-2 variants and the respiratory syncytial virus (RSV).
    Nahhas AF; Webster TJ
    Colloids Surf B Biointerfaces; 2024 Jan; 233():113638. PubMed ID: 37995630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First identification of the SARS-COV-2/XBB.1.5 sublineage among indigenous COVID-19 cases through the influenza sentinel surveillance system in Niger.
    Lagare A; Faye M; Issa M; Hamidou O; Bienvenu B; Mohamed A; Aoula B; Moumouni K; Hassane F; Otto YA; Tambwe DDK; Tassiou EI; Seini H; Faye O; Jambou R
    Heliyon; 2023 Nov; 9(11):e20916. PubMed ID: 37954288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.